GeneCentric’s Lung Subtyping Predictor (LSP™) provides a comprehensive and objective picture of lung tumor biology by identifying tumor subtypes with greater reproducibility than has ever been possible with morphology-based methods. With our pharmaceutical and laboratory partners, LSP™ is changing the taxonomy of lung cancer to improve drug candidate selection and clinical trial design, and provide better treatment guidance for clinicians and patients.
Our first-generation LSP™ classifies tumors into squamous, adenocarcinoma and neuroendocrine (small cell and carcinoid) lung cancer with more reproducibility than traditional methods. LSP™ was independently redeveloped and validated by our commercial partner, Laboratory Corporation of America (LabCorp®), and is available as HistoPlusSM: Lung Cancer.
GeneCentric’s second-generation LSP™, currently undergoing validation, builds on HistoPlusSM: Lung Cancer, further classifying adenocarcinoma subtypes with differential drug response profiles, prognosis, and risk of brain metastasis. LSP™ derived subtypes provide unprecedented insights into therapeutic response for patient management and drug development.